NYSEAMERICAN:NAVB Navidea Biopharmaceuticals - NAVB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.32 +0.04 (+14.29%) (As of 03/30/2023 04:00 PM ET) Add Compare Share Share Today's Range$0.28▼$0.3350-Day Range N/A52-Week Range$0.16▼$1.24Volume258,078 shsAverage Volume147,005 shsMarket Capitalization$10.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) StockNavidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.Read More Receive NAVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NAVB Stock News HeadlinesMarch 24, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. (AMEX:NAVB) Q4 2022 Earnings Call TranscriptMarch 22, 2023 | finance.yahoo.comQ4 2022 Navidea Biopharmaceuticals Inc Earnings CallMarch 30, 2023 | Porter & Company (Ad)Biden’s Big Lie…Biden is about to steal the 2024 election... Not through voter suppression, collision with Big Tech, or anything else you might be thinking of. March 21, 2023 | finance.yahoo.comNavidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial ResultsMarch 15, 2023 | finance.yahoo.comNavidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business UpdateJanuary 24, 2023 | reuters.comNAVB.PH - | Stock Price & Latest News | ReutersJanuary 3, 2023 | msn.comNavidea stock soars ~25% on upcoming US patent linked to cancer drug pipelineDecember 28, 2022 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. (AMEX:NAVB) Q3 2022 Earnings Call TranscriptMarch 30, 2023 | Porter & Company (Ad)Biden’s Big Lie…Biden is about to steal the 2024 election... Not through voter suppression, collision with Big Tech, or anything else you might be thinking of. November 30, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Files Appeal in CRG CaseNovember 28, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid ArthritisNovember 15, 2022 | seekingalpha.comNavidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Call TranscriptNovember 14, 2022 | finance.yahoo.comCORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial ResultsNovember 14, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Reports Third Quarter 2022 Financial ResultsOctober 5, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual MeetingSeptember 30, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of StockholdersSeptember 27, 2022 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. (NAVB)September 15, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual MeetingSeptember 1, 2022 | markets.businessinsider.comNavidea Biopharma To Assess Court's Judgment In Case Involving Attorney's FeesSeptember 1, 2022 | nasdaq.comNavidea Opens New Sites In Phase 3 Trial In Rheumatoid Arthritis; Terminates MOU With JubilantSeptember 1, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant RadiopharmaAugust 30, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business UpdateAugust 18, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights OfferingAugust 4, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights OfferingAugust 1, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in AustraliaAugust 1, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights OfferingJuly 25, 2022 | finance.yahoo.comNavidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIVSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NAVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NAVB Company Calendar Last Earnings11/10/2021Today3/30/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Diagnostic substances Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSEAMERICAN:NAVB Previous SymbolNYSEMKT:NAVB CUSIP63937X10 CIK810509 Webwww.navidea.com Phone(614) 793-7500Fax614-793-7522Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,730,000.00 Net MarginsN/A Pretax Margin-13,229.31% Return on Equity-517.32% Return on Assets-322.92% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.58 Sales & Book Value Annual Sales$530,000.00 Price / Sales19.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book16.00Miscellaneous Outstanding Shares32,151,000Free Float17,619,000Market Cap$10.29 million OptionableOptionable Beta1.36 Key ExecutivesMichael S. RosolSenior VP, Chief Executive & Medical OfficerJeffrey G. SmithVice President-OperationsErika L. EvesVice President-Finance & AdministrationRichard McFerronDirector-Regulatory AffairsKey CompetitorsLucira HealthNASDAQ:LHDXStageZero Life SciencesOTCMKTS:SZLSFVirax Biolabs GroupNASDAQ:VRAXStageZero Life SciencesOTCMKTS:GNWSFStageZero Life SciencesOTCMKTS:GNWSDView All CompetitorsInstitutional OwnershipGroup One Trading L.P.Sold 206,900 shares on 2/9/2023Ownership: 0.000%View All Institutional Transactions NAVB Stock - Frequently Asked Questions Are investors shorting Navidea Biopharmaceuticals? Navidea Biopharmaceuticals saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 438,500 shares, an increase of 38.2% from the January 31st total of 317,300 shares. Based on an average daily trading volume, of 150,900 shares, the days-to-cover ratio is presently 2.9 days. Currently, 2.1% of the shares of the company are short sold. View Navidea Biopharmaceuticals' Short Interest. When is Navidea Biopharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our NAVB earnings forecast. How were Navidea Biopharmaceuticals' earnings last quarter? Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) posted its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.60 million. What other stocks do shareholders of Navidea Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA). What is Navidea Biopharmaceuticals' stock symbol? Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB." Who are Navidea Biopharmaceuticals' major shareholders? Navidea Biopharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include John K Jr Scott and Malcolm G Witter. View institutional ownership trends. How do I buy shares of Navidea Biopharmaceuticals? Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Navidea Biopharmaceuticals' stock price today? One share of NAVB stock can currently be purchased for approximately $0.32. How much money does Navidea Biopharmaceuticals make? Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) has a market capitalization of $10.29 million and generates $530,000.00 in revenue each year. The biopharmaceutical company earns $-11,730,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. How can I contact Navidea Biopharmaceuticals? Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The official website for the company is www.navidea.com. The biopharmaceutical company can be reached via phone at (614) 793-7500, via email at ir@navidea.com, or via fax at 614-793-7522. This page (NYSEAMERICAN:NAVB) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.